GSK recieves approval for an age expansion, making them the first respiratory syncytial virus vaccine for adults aged 50-59 at increased risk

GSK announces that the EC has authorised Arexvy for active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults aged 50-59 who are at increased risk. Since June 2023, GSK’s RSV vaccine has been approved in Europe for adults aged 60 and over for the prevention of RSV-LRTD.

However, adults with underlying medical conditions, such as chronic obstructive pulmonary disease, asthma, heart failure and diabetes are at increased risk for severe consequences from an RSV infection compared to those without these conditions.

Approximately 65 million adults aged between 50 and 59 in the European Union/European Economic Area, with an estimated 20 million of these people having at least one underlying medical condition that puts them at increased risk for RSV disease.

Tony Wood, Chief Scientific Officer, GSK, said: “Today’s approval reflects the importance of broadening the benefits of RSV immunisation to adults aged 50-59 who are at increased risk. RSV infection can have a significant impact on the health of older adults and particularly those with certain existing medical conditions, which can add pressure onto healthcare systems. As we enter the RSV season, we are pleased to be the first to deliver a vaccine to help protect more people in Europe from RSV-LRTD.”

Prof. Dr. Tino F. Schwarz, Klinikum Würzburg Mitte, Würzburg, Germany said: “There are a great number of patients in the age-group 50-59 years living with certain underlying medical conditions with an increased risk for severe RSV infection. These patients are likely to benefit from the extension of the age indication of the RSV vaccine, helping to reduce the burden of disease of RSV associated LRTDs. I hope that the NITAGs in Europe will rapidly adapt the indication of RSV vaccination to include these patients”.

---

---

Related Topics and Keywords

GSK’s Arexvy, respiratory syncytial virus (RSV), rsv, vaccine